NASDAQ:BIOL

BIOLASE (BIOL) Stock Forecast, Price & News

$0.07

0.00 (0.00%)

(As of 06/9/2023 ET)

Compare

Today's Range: $0.07
▼
$0.08
50-Day Range: $0.07
▼
$0.34
52-Week Range: $0.06
▼
$5.94

Volume: 3.59 million shs
Average Volume: 2.53 million shs
Market Capitalization: $2.31 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.63

BIOLASE MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 7,511.6% Upside
$5.63 Price Target
Short Interest: Healthy
3.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.20
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
BIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.63, BIOLASE has a forecasted upside of 7,511.6% from its current price of $0.07.
Amount of Analyst Coverage
BIOLASE has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.69% of the float of BIOLASE has been sold short.
Short Interest Ratio / Days to Cover
BIOLASE has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BIOLASE has recently increased by 4.40%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
BIOLASE does not currently pay a dividend.
Dividend Growth
BIOLASE does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BIOL.

2.3

News and Social Media Coverage

News Sentiment
BIOLASE has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for BIOLASE this week, compared to 2 articles on an average week.
Search Interest
Only 11 people have searched for BIOL on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.
MarketBeat Follows
9 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BIOLASE insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.52% of the stock of BIOLASE is held by insiders.
Percentage Held by Institutions
Only 20.68% of the stock of BIOLASE is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of BIOLASE is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BIOLASE is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BIOLASE has a P/B Ratio of 0.12. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BIOLASE (NASDAQ:BIOL) Stock

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

BIOL Stock News Headlines

June 7, 2023 | markets.businessinsider.com

Maxim Group Sticks to Their Buy Rating for Biolase (BIOL)

June 5, 2023 | finance.yahoo.com

BIOLASE ANNOUNCES DISTRIBUTION OF SERIES I PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK

June 10, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

June 5, 2023 | marketwatch.com

Biolase to Cut 20% of Workforce

June 5, 2023 | msn.com

BIOLASE to cut 20% of US workforce to achieve sales and profitability goals

June 3, 2023 | americanbankingnews.com

BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com

June 1, 2023 | nasdaq.com

Lake Street Maintains Biolase (BIOL) Buy Recommendation

May 31, 2023 | americanbankingnews.com

BIOLASE (NASDAQ:BIOL) PT Lowered to $1.50 at Lake Street Capital

June 10, 2023 | Vector Vest (Ad)

Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 29, 2023 | americanbankingnews.com

Insider Buying: BIOLASE, Inc. (NASDAQ:BIOL) Major Shareholder Acquires $797,837.91 in Stock

May 26, 2023 | finance.yahoo.com

BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants

May 25, 2023 | americanbankingnews.com

BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com

May 24, 2023 | marketwatch.com

Biolase Hits 52-Week Low of 7 Cents After Offering Prices

May 24, 2023 | benzinga.com

Biolase shares are trading lower after the company announced the pricing of a $4.5 million underwritten public offering.

May 24, 2023 | finance.yahoo.com

BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants

May 17, 2023 | americanbankingnews.com

BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com

May 13, 2023 | marketwatch.com

Global Electronic Caries Monitors (ECM) Market Size 2023-2031 Technological Innovations by Absolute Reports | with [119 Pages]

May 11, 2023 | finance.yahoo.com

BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023

May 10, 2023 | msn.com

Earnings Outlook For Biolase

May 10, 2023 | markets.businessinsider.com

Biolase earnings: here's what Wall Street expects

May 10, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

May 10, 2023 | marketwatch.com

Laser Medical Instrument Market Size, Business Segments, Innovative Strategies And Outlook by 2030| El.En., Lumenis, BIOLASE

May 9, 2023 | americanbankingnews.com

BIOLASE (BIOL) Scheduled to Post Quarterly Earnings on Thursday

May 4, 2023 | finance.yahoo.com

BIOLASE TO REPORT FIRST QUARTER 2023 RESULTS ON MAY 11, 2023

April 22, 2023 | marketwatch.com

Global Dental Products Market by [2023-2029] with Revenue Outsourcing

April 15, 2023 | americanbankingnews.com

Short Interest in BIOLASE, Inc. (NASDAQ:BIOL) Increases By 127.0%

April 9, 2023 | marketwatch.com

Dental Hand Instruments Market Facts and Figures By 2030

See More Headlines

BIOL Price History

30 days | 90 days | 365 days | Advanced Chart

BIOL Company Calendar

Last Earnings: 3/28/2023
Today: 6/10/2023
Next Earnings (Estimated): 8/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Dental equipment & supplies
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BIOL
Previous Symbol: NASDAQ:BLTI
CUSIP: N/A
CIK: 811240
Web: www.biolase.com
Phone: (949) 361-1200
Fax: 949-273-6677
Employees: 158
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $5.63
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +7,511.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,630,000.00
Net Margins: -60.92%
Pretax Margin: -60.73%
Return on Equity: -244.91%
Return on Assets: -68.35%

Debt

Debt-to-Equity Ratio: 1.53
Current Ratio: 1.68
Quick Ratio: 0.75

Sales & Book Value

Annual Sales: $48.46 million
Price / Sales: 0.05
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.63 per share
Price / Book: 0.12

Miscellaneous

Outstanding Shares: 31,300,000
Free Float: 31,139,000
Market Cap: $2.31 million
Optionable: Not Optionable
Beta: 1.37

Key Executives

John R. Beaver
President, Chief Executive Officer & Director

Steven Sandor
Chief Operating Officer

Jennifer Brighton
Chief Financial Officer

Russell Morrow
Chief Dental Officer

William E. Brown
Vice President-Innovation & Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIOL Stock - Frequently Asked Questions

Should I buy or sell BIOLASE stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings or view top-rated stocks.
What is BIOLASE's stock price forecast for 2023?: 2 Wall Street research analysts have issued twelve-month price objectives for BIOLASE's shares. Their BIOL share price forecasts range from $1.50 to $14.00. On average, they expect the company's share price to reach $5.63 in the next year. This suggests a possible upside of 7,511.6% from the stock's current price.
View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts.
How have BIOL shares performed in 2023?: BIOLASE's stock was trading at $0.65 at the beginning of the year. Since then, BIOL stock has decreased by 88.6% and is now trading at $0.0739.
View the best growth stocks for 2023 here.
When is BIOLASE's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our BIOL earnings forecast.
How were BIOLASE's earnings last quarter?: BIOLASE, Inc. (NASDAQ:BIOL) announced its earnings results on Tuesday, March, 28th. The medical technology company reported ($1.28) EPS for the quarter. The medical technology company had revenue of $14.05 million for the quarter. BIOLASE had a negative trailing twelve-month return on equity of 244.91% and a negative net margin of 60.92%.
When did BIOLASE's stock split?: BIOLASE shares reverse split on the morning of Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.
What guidance has BIOLASE issued on next quarter's earnings?: BIOLASE updated its FY 2023 earnings guidance on Friday, May, 26th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $60.58M-, compared to the consensus revenue estimate of $59.91 million.
What is John R. Beaver's approval rating as BIOLASE's CEO?: 4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).
What is BIOLASE's stock symbol?: BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."
Who are BIOLASE's major shareholders?: BIOLASE's stock is owned by many different institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (10.34%) and Renaissance Technologies LLC (0.53%). Insiders that own company stock include Education Foundation Schuler, John R Beaver, John R Beaver and Jonathan T Md Lord.
View institutional ownership trends.
How do I buy shares of BIOLASE?: Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BIOLASE's stock price today?: One share of BIOL stock can currently be purchased for approximately $0.07.
How much money does BIOLASE make?: BIOLASE (NASDAQ:BIOL) has a market capitalization of $2.31 million and generates $48.46 million in revenue each year. The medical technology company earns $-28,630,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis.
How many employees does BIOLASE have?: The company employs 158 workers across the globe.
How can I contact BIOLASE?: BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677.

This page (NASDAQ:BIOL) was last updated on 6/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial